Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.3.0.814
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2015
Dec. 31, 2010
Sep. 30, 2015
Mar. 31, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Jul. 31, 2015
Dec. 31, 2014
Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Deferred revenue     $ 254,100,000     $ 254,100,000     $ 6,700,000  
Grant repayment     0 $ 25,900,000 $ 0 25,889,000 $ 0      
Pfizer | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Non-refundable upfront payment $ 295,000,000                  
Additional milestone payment to be received 275,000,000                  
Revenue from sale of intellectual property     17,700,000     47,800,000        
Deferred revenue     247,200,000     247,200,000        
Tesaro                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Additional milestone payment to be received   $ 30,000,000                
Upfront payment under license agreements   6,000,000                
Milestone payment received           5,000,000        
Additional milestone payment   $ 85,000,000                
Period from first commercial sale   12 years                
Merck | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Non-refundable upfront payment           25,000,000        
Additional milestone payment to be received           5,000,000        
Milestone payment received           20,000,000        
Amount payable each year           $ 5,000,000        
Period for yearly payment           4 years        
Intangible assets, estimated useful lives           13 years        
Accrued Expenses | Pfizer | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Deferred revenue     70,600,000     $ 70,600,000        
Accrued Expenses | Merck | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Milestone payment received           5,000,000        
Other Noncurrent Liabilities | Pfizer | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Deferred revenue     $ 176,600,000     176,600,000        
Other Noncurrent Liabilities | Merck | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Milestone payment received           $ 15,000,000        
Minimum                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Intangible assets, estimated useful lives           3 years        
Minimum | Pfizer | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Milestone payment ranges 20,000,000                  
Maximum                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Intangible assets, estimated useful lives           20 years        
Maximum | Pfizer | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Milestone payment ranges $ 90,000,000                  
Rxi Pharmaceuticals Corporation                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Milestone payments                   $ 50,000,000
Pharmsynthez                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Ownership percentage     17.00%     17.00%        
Pharmsynthez Note Receivable | Notes | Pharmsynthez                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Debt face amount               $ 3,000,000.0